
Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5598 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TAI-95
CAS:<p>TAI-95 is an inhibitor of highly expressed cancer protein 1 (Hec1).</p>Fórmula:C24H23N5O3S2Cor e Forma:SolidPeso molecular:493.60VDR agonist 1
CAS:<p>Compound 28 is a nonsteroidal VDR agonist with 690 nM potency, inducing cell cycle arrest and apoptosis in MCF-7 cells.</p>Fórmula:C32H51N3O2Pureza:98%Cor e Forma:SolidPeso molecular:509.77RIPK1-IN-28
CAS:<p>RIPK1-IN-28 (compound 13) is an orally active inhibitor of RIPK1. It exhibits inhibitory effects on human I2.1 and Hepa1-6 cells, with IC50 values of 0.4 and 1.2 nM, respectively.</p>Fórmula:C27H24N4O4Cor e Forma:SolidPeso molecular:468.504PLK1-IN-13
CAS:<p>PLK1-IN-13 is a selective, orally active PLK1 inhibitor with an IC50 of 0.27 nM. It also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM). PLK1-IN-13 induces cell cycle arrest at the G2 phase, promotes apoptosis, and downregulates the transcription of the cancer-associated oncogene c-MYC. This compound inhibits tumor growth and is applicable for research in acute myeloid leukemia (AML).</p>Fórmula:C29H39N9O2SCor e Forma:SolidPeso molecular:577.744Microtubulin-IN-1
CAS:<p>Microtubulin-IN-1 (Compound 8g) is an inhibitor of microtubulin, targeting the colchicine-binding site to disrupt tubulin integrity and induce upregulation of p53 protein expression. It exhibits antiproliferative activity across various cancer cell lines, including NCI-H460, BxPC-3, and HT-29, with IC50 values of 2.4, 1.6, and 2.07 nM, respectively. Additionally, Microtubulin-IN-1 induces cell cycle arrest at the G2/M phase and apoptosis in NCI-H460 cells.</p>Fórmula:C25H21FN4O3Cor e Forma:SolidPeso molecular:444.458SL-176
CAS:<p>SL-176, a WIP1 inhibitor, when combined with GSK-J4, can induce cell cycle arrest and apoptosis (apoptosis), thereby inhibiting tumor growth both in vitro and in vivo.</p>Fórmula:C24H48O4Si2Cor e Forma:SolidPeso molecular:456.806Autophagy inducer 7
CAS:<p>Autophagyinducer 7 (Compound SSA) serves as an inducer of autophagy (Autophagy) and apoptosis (Apoptosis). It stimulates autophagy by inhibiting Akt/mTOR signaling and the expression of downstream proteins. Additionally, Autophagyinducer 7 suppresses DNA synthesis and causes G0-G1 cell cycle arrest, ultimately inhibiting the growth of tumor cells.</p>Fórmula:C24H27FN2OSCor e Forma:SolidPeso molecular:410.547PD-L1/HDAC-IN-1
CAS:<p>PD-L1/HDAC-IN-1 (Compound 14) is an inhibitor of PD-L1 and HDAC, effectively blocking PD-1/PD-L1 interaction as well as HDAC2 and HDAC3 with IC50 values of 88.10, 27.98, and 14.47 nM, respectively. It exhibits mild cytotoxicity in MCF-7 cells (IC50=19.34 μM) and enhances the expression of PD-L1 and CXCL10, promoting antitumor immune responses by recruiting T cell infiltration into the tumor microenvironment (TME).</p>Fórmula:C42H46ClN3O7Cor e Forma:SolidPeso molecular:740.284CDK2/9-IN-1
CAS:<p>CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9, with IC50 values of 0.004 μM and 0.009 μM for CDK2 and CDK9, respectively. It induces apoptosis by regulating G2/M cell cycle arrest and exhibits antitumor activity.</p>Fórmula:C14H14N6O2S2Cor e Forma:SolidPeso molecular:362.43Antitumor agent-58
<p>Antitumor agent-58 suppresses tumor growth, colony formation, cell migration, and induces mitochondrial dysfunction in MGC-803 cells.</p>Fórmula:C27H28F3N9SCor e Forma:SolidPeso molecular:567.63Silvestrol
CAS:<p>Silvestrol is a eukaryotic translation initiation factor 4A inhibitor. Silvestrol causes autophagy and caspase-mediated apoptosis.</p>Fórmula:C34H38O13Pureza:98%Cor e Forma:SolidPeso molecular:654.66T0080
CAS:<p>T0080 is an FPR-1 antagonist. It reduces apoptosis (Apoptosis) and inhibits the production of reactive oxygen species (ROS) and pro-inflammatory cytokines (TNF-α and IL-1β) in plaque macrophages within ApoE−/− mouse models, thereby slowing the progression of atherosclerosis.</p>Fórmula:C24H22F3N3O3Cor e Forma:SolidPeso molecular:457.45Soquelitinib
CAS:<p>Soquelitinib (CPI-818) is a selective ITK inhibitor, inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Fórmula:C25H30N4O4S2Pureza:99.54%Cor e Forma:SolidPeso molecular:514.66Antitumor agent-72
CAS:<p>Antitumor agent-72 (compound 6w) is a potent anticancer agent that exhibits its anticancer activity by inducing apoptosis via caspase-3 activation and PARP</p>Fórmula:C25H20ClNO6Cor e Forma:SolidPeso molecular:465.88Microtubule inhibitor 2
<p>Microtubule inhibitor 2: potent, selective, oral, induces ferroptosis, strong antitumor effect.</p>Fórmula:C20H23NO7Cor e Forma:SolidPeso molecular:389.4microRNA-21-IN-1
CAS:<p>microRNA-21-IN-1: microRNA inhibitor, curbs HeLa/HCT-116 growth (IC50: 5.5/2.8 μM), induces HeLa apoptosis, elevates PTEN/EGR1/SLIT2, for cancer research.</p>Fórmula:C30H37FN6O3Cor e Forma:SolidPeso molecular:548.65APD-94
CAS:<p>APD-94 is a dual inhibitor targeting tubulin and Bmi-1. It disrupts the normal polymerization of tubulin and suppresses the expression of Bmi-1. This compound induces cell cycle arrest at the G2/M phase and triggers apoptosis, thereby inhibiting cancer cell proliferation. Additionally, APD-94 inhibits the growth of HT29 cell xenograft tumors in NOD/SCID mice and is applicable to colorectal cancer research.</p>Fórmula:C18H17N3O4Cor e Forma:SolidPeso molecular:339.345M3258
CAS:<p>LMP7-IN-1 may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer, is an inhibitor of</p>Fórmula:C17H20BNO5Pureza:98%Cor e Forma:SolidPeso molecular:329.16STAT3-IN-9
<p>STAT3-IN-9 hinders STAT3 at Tyr705, doesn't affect STAT1 Tyr701, induces apoptosis, and arrests cells in G2/M phase.</p>Fórmula:C22H21N3O4Cor e Forma:SolidPeso molecular:391.42LL-Z 1640-4
CAS:A signal-specific JNK/p38 pathway and TAK 1 inhibitorFórmula:C19H24O7Pureza:98%Cor e Forma:SolidPeso molecular:364.39IMB5046
CAS:<p>IMB5046 is a microtubule inhibitor that induces apoptosis (cell death) by obstructing the G2/M phase of the cell cycle. It possesses antitumor properties.</p>Fórmula:C19H20N2O5SCor e Forma:SolidPeso molecular:388.438MRK003
CAS:<p>MRK003, a γ-secretase inhibitor, induces apoptosis, halts cell growth in myeloma/NHL, and affects notch signaling and PI3K/Akt pathway.</p>Fórmula:C25H31F6N3O2SCor e Forma:SolidPeso molecular:551.59K20
<p>K20 selectively inhibits KRas G12C (IC50: 1.16 nM), shows anticancer activity in H358 cells (IC50: 0.78 μM), and induces apoptosis via Erk dephosphorylation.</p>Fórmula:C24H20Cl2F4N4O2Cor e Forma:SolidPeso molecular:543.34EGFR-IN-161
CAS:<p>EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.</p>Fórmula:C33H36Cl2N8O2Cor e Forma:SolidPeso molecular:647.597SMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1, binding to this target with a dissociation constant (Kd) of 37.4 μM. It demonstrates efficacy in inhibiting the proliferation of cancer cells and tumor progression. Specifically, SMIP34 is effective in breast cancer research, showing activity against wild-type (WT), mutant (MT) estrogen receptor-positive (ER+), and treatment-resistant (TR)-ER+ breast cancers.</p>Fórmula:C25H32ClN5O3Cor e Forma:SolidPeso molecular:486.01Lysosomal P-gp targeted agent 1
CAS:<p>Lysosomal P-gp targeted agent 1 (Compound 14) is an antitumor drug that targets lysosomal P-glycoprotein (Pgp). It is selectively transported to lysosomes via overexpressed Pgp, releasing nitric oxide that generates reactive oxygen species (ROS), causing lysosomal membrane permeabilization (LMP) and inducing apoptosis. This compound can overcome resistance mediated by P-glycoprotein, leading to cell cycle arrest while maintaining relatively low toxicity to normal cells. It exhibits antitumor activity by significantly inhibiting tumor growth.</p>Fórmula:C39H34N2O9SCor e Forma:SolidPeso molecular:706.76NSD2-IN-1
CAS:<p>NSD2-IN-1: potent, selective NSD2-PWWP1 inhibitor, IC50 0.11 μM, induces gene expression changes, apoptosis, cell cycle arrest.</p>Fórmula:C29H31N5Cor e Forma:SolidPeso molecular:449.59RET-IN-9
CAS:<p>RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.</p>Fórmula:C26H27N9OCor e Forma:SolidPeso molecular:481.55PD-1/PD-L1-IN-17
<p>PD-1/PD-L1-IN-17 (Compound P20) is a potent PD-1/PD-L1 inhibitor (IC50: 26.8 nM).</p>Fórmula:C23H20ClN3O4Cor e Forma:SolidPeso molecular:437.88Topoisomerase I/II inhibitor 4
<p>Topoisomerase I/II inhibitor 4 halts cell growth and spread, induces apoptosis, and is used in liver cancer research.</p>Fórmula:C27H21N5O6Cor e Forma:SolidPeso molecular:511.49MP-010
CAS:<p>MP-010 is an FKBP12 ligand that regulates cytosolic calcium by stabilizing RyR channel activity. It facilitates functional improvement in SOD1G93A mice with amyotrophic lateral sclerosis (ALS), evidenced by enhanced motor coordination, increased integrity of neuromuscular junctions, and significantly higher spinal motor neuron survival rates. MP-010 is applicable for research in the field of neurological disorders.</p>Fórmula:C14H20N4O2SCor e Forma:SolidPeso molecular:308.399BRD-K44839765
CAS:<p>BRD-K44839765 selectively targets Bcl-2, exhibiting an IC50 of 5.6 μM in IMR-90 cells. This compound is also orally active.</p>Fórmula:C23H19N3O2S2Cor e Forma:SolidPeso molecular:433.55EGFR-IN-44
<p>EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.</p>Fórmula:C27H29ClN6O2SCor e Forma:SolidPeso molecular:537.08Oxamic acid
CAS:<p>Oxamic acid is an inhibitor of LDH-A and exhibits antitumor activity. It demonstrates antiproliferative effects on cancer cells and can induce apoptosis.</p>Fórmula:C2H3NO3Cor e Forma:SolidPeso molecular:89.05RIP3 activator 1
CAS:<p>RIP3 Activator 1 (compound C8) is an effective RIP3 activator that inhibits cell growth and induces necroptotic cell death (necroptosis) and autophagy through the RIP3/p62/Keap1 signaling pathway. Additionally, this compound enhances the expression of p-MLKL and promotes the accumulation of LC3-II and p62 proteins.</p>Fórmula:C26H50N4O3Cor e Forma:SolidPeso molecular:466.7JR5-26B
CAS:<p>JR5-26B is an orally active apoptosis (apoptosis) inducer. It induces cell death via copper-mediated apoptosis and necroptosis (necroptosis). JR5-26B exhibits antiproliferative activity against MIA PaCa-2, PANC-1, PAN02, SU.86.86, and KPC-2 cells, with IC50 values of 0.6, 4.4, 8.0, 1.1, and 3.4 μM, respectively.</p>Fórmula:C19H17FN6OCor e Forma:SolidPeso molecular:364.38PD-1/PD-L1-IN-55
CAS:<p>PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.</p>Fórmula:C25H23ClN2O3Cor e Forma:SolidPeso molecular:434.92XIAP/cIAP1 antagonist-1
<p>Potent oral XIAP/cIAP1 inhibitor with EC50s: XIAP 5.1 nM, cIAP1 0.32 nM; curbs tumor growth in vivo.</p>Cor e Forma:SolidGlyphosate isopropylammonium
CAS:<p>Glyphosate isopropylammonium is a broad-spectrum, non-selective systemic biocide derived from the amino acid glycine. It inhibits the enzyme activity of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) in the shikimate pathway, blocking the synthesis of aromatic amino acids tyrosine, phenylalanine, and tryptophan. Additionally, Glyphosate isopropylammonium induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, leading to neuronal death through autophagy, necrosis, or apoptosis, resulting in behavioral and motor disturbances.</p>Fórmula:C6H17N2O5PPeso molecular:228.18VDX-111
CAS:<p>VDX-111, an analog of vitamin D, exhibits cytotoxicity in ovarian cancer cells by upregulating the RIPK1/RIPK3 pathway and inducing necroptosis. It also promotes the expression of cytokines and demonstrates antitumor activity in a mouse model [1].</p>Fórmula:C29H45BrO4Cor e Forma:SolidPeso molecular:537.57VEGFR-2-IN-14
<p>VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Fórmula:C24H23N3O3SCor e Forma:SolidPeso molecular:433.52Tubulin polymerization-IN-61
CAS:<p>Tubulin polymerization-IN-61 (Compound 9a), a tubulin polymerization inhibitor, disrupts the microtubule skeleton, arrests the cell cycle at the G2/M phase, induces Apoptosis, and impedes cancer cell migration and colony formation. This compound demonstrates antitumor efficacy in vivo within the 4T1 xenograft model [1].</p>Fórmula:C22H21N3O5Cor e Forma:SolidPeso molecular:407.42[D-Leu-4]-OB3
CAS:[D-Leu-4]-OB3 suppresses the expression of genes associated with inflammation, proliferation, and metastasis, as well as the expression of PD-L1.Fórmula:C29H50N8O12SCor e Forma:SolidPeso molecular:734.82GPD-1116
CAS:<p>GPD-1116 is an orally active inhibitor of phosphodiesterase (PDE)4 and PDE1. The compound effectively reduces smoke-induced apoptosis in lung cells. Additionally, GPD-1116 has shown efficacy in various animal disease models, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma, and pulmonary arterial hypertension.</p>Fórmula:C22H16N4OCor e Forma:SolidPeso molecular:352.39YK5
CAS:<p>YK5 is an allosteric inhibitor pocket of Hsp70 and represents a previously unknown chemical tool to investigate cellular mechanisms associated with Hsp70.</p>Fórmula:C18H24N8O3SPureza:98%Cor e Forma:SolidPeso molecular:432.50HDL-16
CAS:<p>HDL-16 is a highly effective P2Y14R antagonist with anti-colitis effects, targeting P2Y14R in intestinal epithelial cells to alleviate ulcerative colitis.</p>Fórmula:C14H11BrN2OPureza:97.58%Cor e Forma:SolidPeso molecular:303.15Spicamycin
CAS:<p>Spicamycin can be used as a potent inducer of differentiation of human myeloid leukemia cells (HL-60) and murine myeloid leukemia cells (M1).</p>Fórmula:C30H51N7O7Cor e Forma:SolidPeso molecular:621.77Metamizole hemimagnesium
CAS:<p>Metamizole (Dipyrone) hemimagnesium is an anti-inflammatory and antioxidant compound known for its ability to reduce fever. It decreases levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Additionally, Metamizole hemimagnesium acts as an orally active cyclooxygenase (COX) inhibitor, suppressing cell proliferation and promoting apoptosis. It is utilized in the study of inflammation and fever.</p>Fórmula:C13H17MgN3O4SCor e Forma:SolidPeso molecular:335.662Tofacitinib Prodrug-1
<p>Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.</p>Fórmula:C36H39ClN10O7Cor e Forma:SolidPeso molecular:759.21SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5QTX125 TFA
<p>QTX125 TFA: Potent, selective HDAC6 inhibitor with antitumor effects.</p>Fórmula:C25H20F3N3O7Cor e Forma:SolidPeso molecular:531.44WEHI-9625
CAS:<p>WEHI-9625 is a tricyclic sulfone small molecule apoptosis inhibitor (EC50: 69 nM).</p>Fórmula:C34H27NO5S2Pureza:98%Cor e Forma:SolidPeso molecular:593.71ER covalent antagonist-1
CAS:<p>ER covalent antagonist-1 (Compound 39D) acts as an antagonist of the estrogen receptor α (ERα). This compound inhibits the proliferation of ERα-positive MCF-7 cells with an IC50 of 0.98 μM, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. Additionally, ER covalent antagonist-1 demonstrates antitumor activity in mouse models.</p>Fórmula:C33H32N2O5SCor e Forma:SolidPeso molecular:568.683HC-7366
CAS:<p>HC-7366 (GCN2 modulator-1) is an orally active GCN2 kinase activator with antitumor activity, inducing tumor growth inhibition.</p>Fórmula:C20H15ClF2N6O4SPureza:99.84%Cor e Forma:SolidPeso molecular:508.89Antiproliferative agent-63
CAS:<p>Antiproliferative agent-63 (compound 4d) is a cyclic analog of cannabidiol that acts as an anticancer agent. It demonstrates favorable activity against breast and colorectal cancer. Moreover, this compound can arrest the cell cycle in the G1 phase and induce apoptosis through the mitochondrial pathway in breast cancer cell lines.</p>Fórmula:C27H41NO2Cor e Forma:SolidPeso molecular:411.62Anticancer agent 45
<p>Anticancer agent 46, potent and selective, induces apoptosis, is cytotoxic to cancer cells, with low toxicity to human lymphocytes.</p>Fórmula:C22H14ClN3O6S2Cor e Forma:SolidPeso molecular:515.95MG-B-28
<p>MG-B-28, a BTLA-HVEM inhibitor, demonstrates an IC50 value of 906 nM. It promotes T cell activation dose-dependently by inhibiting the interaction between BTLA and HVEM.</p>Fórmula:C28H25N5O3Cor e Forma:SolidPeso molecular:479.53Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18Antitumor agent-184
CAS:Antitumor Agent-184 (compound 12aa) triggers apoptosis in various cell lines, exhibiting IC50 values of 2.35 μM in B16-F10 cells, 7.32 μM in 4T1 cells, and 10.31 μM in CT26 cells.Fórmula:C22H16N4O2SCor e Forma:SolidPeso molecular:400.45LSD1-IN-21
<p>LSD1-IN-21: potent LSD1 inhibitor, crosses blood-brain barrier, IC50 of 0.956 μM; lowers TNF-α, anti-cancer, anti-inflammatory.</p>Fórmula:C24H25N5O2SCor e Forma:SolidPeso molecular:447.55EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Fórmula:C18H21N5O3SCor e Forma:SolidPeso molecular:387.46ZSH-512
CAS:<p>ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.</p>Fórmula:C20H21N3O3SCor e Forma:SolidPeso molecular:383.464Topoisomerase II inhibitor 20 TFA
<p>TopoisomeraseII Inhibitor 20 TFA is a potent inhibitor of topoisomerase II with an IC50 of 0.98 µM. It can induce cell apoptosis and exhibits broad-spectrum anticancer activity.</p>Fórmula:C24H24F5N5O4SCor e Forma:SolidPeso molecular:573.54PD-1-IN-17 TFA
<p>PD-1-IN-17 TFA is a potent PD-1 inhibitor, blocking 92% of splenocyte growth at 100 nM.</p>Fórmula:C15H23F3N6O9Cor e Forma:SolidPeso molecular:488.37FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35NDs-IN-1
CAS:NDs-IN-1 (Compound 3g) is a novel non-covalent multi-target inhibitor that inhibits the activities of key enzymes such as hBACE-1, hAChE, and hMAO-B, and is primarily used in the study of neurodegenerative diseases [1].Fórmula:C20H18N2O2Peso molecular:318.37PD-1/PD-L1-IN-15
<p>PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy.</p>Fórmula:C32H30N4O3Cor e Forma:SolidPeso molecular:518.61CP-31398
CAS:<p>CP-31398 stabilizes the active conformation of p53 in cancer cells with either mutated or wild-type p53, enhancing its activity. Additionally, CP-31398 upregulates target genes of p53 such as p21WAF1/Cip1 and KILLER/DR5. This compound possesses tumor-suppressive properties.</p>Fórmula:C22H26N4OCor e Forma:SolidPeso molecular:362.47TP-030-1
CAS:<p>TP-030-1, RIPK1 inhibitor: K(i) hRIPK1 at 3.9nM, IC50 mRIPK1 at 4.2μM; targets inflammation, neurodegeneration research.</p>Fórmula:C23H22N4O3Cor e Forma:SolidPeso molecular:402.45Triphen diol
CAS:<p>Triphen diol, a phenol diol, fights pancreatic cancer & cholangiocarcinoma, inducing apoptosis via caspase-dependent & -independent paths.</p>Fórmula:C22H20O4Cor e Forma:SolidPeso molecular:348.39Z-VA-DL-D-FMK
CAS:Z-VA-DL-D-FMK (Z-VA-DL-D(OH)-FMK) acts as an inhibitor of caspases. It irreversibly binds to caspases, enhancing the sensitivity to TNF-α and stimulating HIV replication in infected T cells ACH-2.Fórmula:C21H28FN3O7Cor e Forma:SolidPeso molecular:453.46CB-184
CAS:<p>CB-184 is a selective ligand for sigma-2 (σ2) receptors, with Ki values of 7436 nM for sigma-1 (σ1) and 13.4 nM for sigma-2 (σ2), and it promotes apoptosis with antitumor activity.</p>Fórmula:C22H21Cl2NO2Cor e Forma:SolidPeso molecular:402.31PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Fórmula:C31H28ClN5OCor e Forma:SolidPeso molecular:522.04TNF-α-IN-14
CAS:<p>TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].</p>Fórmula:C22H26O6Cor e Forma:SolidPeso molecular:386.44AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99Apoptosis inducer 5
<p>Apoptosis Inducer 5, a lignan enantiomer extracted from Crataegus pinnatifida, demonstrates cytotoxic properties through inducing apoptosis and autophagy in</p>Fórmula:C23H26O7Cor e Forma:SolidPeso molecular:414.45VEGFR-2-IN-15
<p>VEGFR-2-IN-15 (Compound 14b) is a potent inhibitor of VEGFR-2. VEGFR-2-IN-15 inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.</p>Fórmula:C23H18ClN3O4SCor e Forma:SolidPeso molecular:467.92mTOR/HDAC6-IN-1
<p>mTOR/HDAC6-IN-1 inhibits HDAC6 (IC50: 56 nM) & mTOR (IC50: 133.7 nM), may treat TNBC by inducing autophagy and apoptosis.</p>Fórmula:C20H20ClN5O2Cor e Forma:SolidPeso molecular:397.86TLBC
CAS:<p>TLBC, a borane-chalcone derivative, exhibits dose-dependent inhibitory effects across various glioma cell lines with IC50 values ranging from 5.5 to 25.5 μM. TLBC induces apoptosis independently of alterations in the tumor suppressor factor p53.</p>Fórmula:C15H12BIO3Cor e Forma:SolidPeso molecular:377.97Tubulin/NRP1-IN-1
CAS:<p>Tubulin/NRP1-IN-1 (compound TN-2) serves as a dual inhibitor targeting both Tubulin and NRP1, exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound notably reduces the viability of prostate tumor cell lines and triggers apoptosis [1].</p>Fórmula:C28H37N5O8Cor e Forma:SolidPeso molecular:571.62ASP9831
CAS:<p>ASP9831 is an orally active PDE4 inhibitor. It suppresses LPS-induced TNF-α production and exhibits anti-inflammatory properties. ASP9831 is useful in the study of steatohepatitis.</p>Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.42Ferroptosis-IN-15
CAS:<p>Ferroptosis-IN-15 (compound 12) serves as an effective inhibitor of ferroptosis, exhibiting EC50 values of 0.76 μM and 0.67 μM in A375 cells and 786-O cells, respectively. It acts as a potential iron chelator and radical-scavenging antioxidant.</p>Fórmula:C17H14O5Cor e Forma:SolidPeso molecular:298.29Lometrexol hydrate
CAS:<p>Lometrexol hydrate, an antipurine antifolate, inhibits GARFT and purine synthesis, leading to cancer cell apoptosis without causing DNA breaks.</p>Fórmula:C21H27N5O7Cor e Forma:SolidPeso molecular:461.475RIPK1-IN-14
CAS:<p>RIPK1-IN-14 inhibits RIPK1 with 92 nM IC50 and reduces necrotic apoptosis in U937 cells.</p>Cor e Forma:SoildSM-433 hydrochloride
<p>SM-433 hydrochloride, a Smac mimetic & IAP inhibitor, binds XIAP BIR3; potent IC50 <1 μM. (Patent WO2008128171A2)</p>Fórmula:C32H44ClN5O4Cor e Forma:SolidPeso molecular:598.18Tubulin inhibitor 14
<p>Tubulin inhibitor 14 blocks NQO2 and microtubule formation, disrupts blood vessels, and may target tumors; IC50 of 1.0 μM.</p>Fórmula:C15H9F2NOCor e Forma:SolidPeso molecular:257.23EGFR-IN-3
<p>EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.</p>Fórmula:C24H18F4N6O2SPureza:98.1%Cor e Forma:SolidPeso molecular:530.5ADH-6
CAS:<p>ADH-6, a tripyridylamide, disrupts mutant p53 aggregates in cancer cells, reviving its function and inducing apoptosis.</p>Fórmula:C29H36N8O9Cor e Forma:SolidPeso molecular:640.64VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61Tubulin inhibitor 13
CAS:<p>Tubulin inhibitor 13 (E27), IC50 16.1 μM, blocks tubulin polymerization, cancer cell migration, and invasion, induces apoptosis.</p>Fórmula:C25H21N3O4Cor e Forma:SolidPeso molecular:427.45TP-030-2
CAS:<p>TP-030-2 is a RIPK1 inhibitor (human K i =0.43 nM ; mouse IC 50 =100 nM) .</p>Fórmula:C23H21BrN4O3Cor e Forma:SolidPeso molecular:481.34PI4KIII β inhibitor 4
CAS:<p>PI4KIII beta inhibitor 4 (Compound 16) is a selective inhibitor of PI4KIIIβ with an IC50 of 0.005 μM. By inhibiting the PI3K/AKT pathway, PI4KIII beta inhibitor 4 induces apoptosis, causes cell cycle arrest, and triggers autophagy in tumor cells. This compound is applicable for tumor research.</p>Fórmula:C24H36N4O6S2Cor e Forma:SolidPeso molecular:540.696BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61GGTI298
CAS:<p>GGTI298 is a potent GGTase I inhibitor; IC50 3μM for Rap1A, >20μM for Ha-Ras.</p>Fórmula:C27H33N3O3SPureza:98%Cor e Forma:SolidPeso molecular:479.63TBC-1
CAS:<p>TBC-1 is a chlorophyll-a derivative that acts as a photosensitizer for photodynamic therapy (PDT). It efficiently generates type I ROS and targets the endoplasmic reticulum. TBC-1 demonstrates in vitro biocompatibility and PDT effectiveness under both normoxic and hypoxic conditions.</p>Fórmula:C31H28BrN3O3Cor e Forma:SolidPeso molecular:570.476Ph-Ph+
<p>Ph-Ph+ is a dimerized phenanthroline derivative with antitumor, antibacterial, and antifungal effects.</p>Fórmula:C24H17N4Cor e Forma:SolidPeso molecular:361.42CDK-IN-9
<p>CDK-IN-9: A potent CDK inhibitor, gels to enhance CDK12/DDB1 binding, targets CDK2/E (IC50: 4 nM), induces apoptosis via dephosphorylation.</p>Fórmula:C21H24N8SCor e Forma:SolidPeso molecular:420.53p38 MAPK-IN-3
<p>Compound 2c is a potent p38α MAPK inhibitor with antitumor effects, enhancing apoptosis and ROS.</p>Fórmula:C22H17BrO2Cor e Forma:SolidPeso molecular:393.27Anticancer agent 64
CAS:<p>Anticancer agent 64 (5m) induces apoptosis, has IC50 2.4μM in CCRF-CEM, activates caspases, cleaves PARP, affects mitochondria.</p>Fórmula:C31H46N2O2SCor e Forma:SolidPeso molecular:510.77Fluvastatin sodium monohydrate
CAS:<p>Fluvastatin (XU 62-320) sodium monohydrate, a fully synthetic competitive HMG-CoA reductase inhibitor, features an IC 50 of 8 nM. This compound also safeguards vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway [1] [2].</p>Fórmula:C24H27FNNaO5Cor e Forma:SolidPeso molecular:451.46p53 Activator 14
CAS:<p>p53 Activator 14 (Compound 7A) is a derivative of Neratinib that can induce DNA damage and activate p53, thereby inhibiting the proliferation of various cancer cells, with an IC50 of 7.21 μM for HCT116 cells. This compound hinders adhesion, migration, and invasion of HCT116 cells, disrupts the cell cycle, and triggers apoptosis. In addition, p53 Activator 14 exhibits anti-tumor properties and inhibits angiogenesis in the chick embryo chorioallantoic membrane (CAM) model.</p>Fórmula:C28H29ClN4O3Cor e Forma:SolidPeso molecular:505.008MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Fórmula:C20H18N4O5Pureza:98%Cor e Forma:SolidPeso molecular:394.38ASK1-IN-7
CAS:<p>ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. This compound is potentially applicable in research involving ASK1 signaling pathways, including studies on cellular stress response, inflammatory response, neurodegenerative diseases, and cardiovascular diseases.</p>Fórmula:C13H8N2O2S2Cor e Forma:SolidPeso molecular:288.345Bcl-2-IN-3
CAS:<p>Bcl-2-IN-3 (Compound 10) is an inhibitor of Bcl-2, utilized in cancer research.</p>Fórmula:C16H16N2O4Cor e Forma:SolidPeso molecular:300.31NLRP3-IN-26
CAS:<p>NLRP3-IN-26 (compound 15Z), with an IC50 of 0.13 μM, functions as an inhibitor of NLRP3. It is applicable in studies involving the DSS-induced colitis model [1].</p>Fórmula:C31H33ClN2O6SCor e Forma:SolidPeso molecular:597.12PI3Kα-IN-8
<p>PI3Kα-IN-8 is a selective inhibitor of PI3Kα (IC50: 0.012 μM).</p>Fórmula:C26H27BrN4O2Cor e Forma:SolidPeso molecular:507.42Tubulin polymerization-IN-6
<p>Compound 5f, a potent tubulin polymerization inhibitor (IC50 = 1.09 μM), blocks cell migration, tube formation, and has anti-angiogenic effects.</p>Fórmula:C19H21NO7Cor e Forma:SolidPeso molecular:375.37EGFR-IN-62
<p>EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.</p>Fórmula:C30H33N9O2Cor e Forma:SolidPeso molecular:551.64ABL-L
CAS:<p>ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway.</p>Fórmula:C29H46O6Cor e Forma:SolidPeso molecular:490.67Laulimalide
CAS:<p>Microtubule stabilizer; halts cancer cell growth (IC50: 3-30 nM); arrests cells in prometaphase; prevents bipolar spindle formation.</p>Fórmula:C30H42O7Cor e Forma:SolidPeso molecular:514.65MB710
CAS:<p>MB710 is an amino-benzothiazole derivative that tightly binds to the Y220C pocket and stabilizes p53-Y220C in vitro.</p>Fórmula:C16H16IN3O3SPureza:99.02%Cor e Forma:SolidPeso molecular:457.29VEGFR-2-IN-18
<p>VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.</p>Fórmula:C20H13ClN4O2Cor e Forma:SolidPeso molecular:376.8TH-6
<p>TH-6, a potent HDAC inhibitor (IC50: HDAC1-0.115, 2-0.135, 3-0.242, 6-0.138, 8-2.120 μM), blocks cell migration, invasion, and has anti-tumor properties.</p>Fórmula:C22H24FN3O5Cor e Forma:SolidPeso molecular:429.44Sinulatumolin E
CAS:<p>Sinulatumolin E, a terpenoid, inhibits TNF-α (IC 50: 3.6 μM); has anti-inflammatory properties.</p>Fórmula:C15H22O2Cor e Forma:SolidPeso molecular:234.33GRP78-IN-1
<p>GRP78-IN-1 binds to GRP78 protein, inhibits cell growth, and triggers apoptosis in breast cancer; has -8.07 kcal/mol binding energy.</p>Fórmula:C21H23FO3Cor e Forma:SolidPeso molecular:342.4NCAO
CAS:<p>N-ω-chloroacetyl-L-ornithine (NCAO) serves as a powerful reversible competitive inhibitor of ornithine decarboxylase (ODC), displaying cytotoxic and antiproliferative properties against various tumor cell lines, with EC50 values spanning from 1 to 50.6 µM. In vitro studies reveal that NCAO promotes Apoptosis and restricts tumor cell migration. Additionally, it demonstrates significant antitumor efficacy in a mouse model, targeting both solid and ascitic tumors using the myeloma (Ag8) cell line. NCAO holds promise in the development of antitumor agents.</p>Fórmula:C7H13ClN2O3Cor e Forma:SolidPeso molecular:208.64HBV/HDV-IN-2
CAS:<p>HBV/HDV-IN-2 (Compd 143) functions as an inhibitor for HBV, HDV, and PD-1/PD-L1, demonstrating an EC 50 of 35 nM in T cell activation.</p>Fórmula:C38H44ClN7O5Cor e Forma:SolidPeso molecular:714.25HDAC/PSMD14-IN-1
CAS:<p>HDAC/PSMD14-IN-1 is a derivative of gambogic acid. It serves as an orally active dual inhibitor targeting PSMD14 and HDAC1, with IC50 values of 238.7 nM and 141.2 nM, respectively. The compound exhibits significant cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). Additionally, HDAC/PSMD14-IN-1 can induce apoptosis. In KYSE30 cell xenograft models in mice, it displays antitumor activity. HDAC/PSMD14-IN-1 is useful for researching esophageal cancer treatment.</p>Fórmula:C20H24N4O3S2Cor e Forma:SolidPeso molecular:432.56Aeroplysinin 1
CAS:<p>Aeroplysinin I is an antibacterial compound from the sponge. It has cytotoxic activity against colon cancer cells by promoting β-catenin degradation.</p>Fórmula:C9H9Br2NO3Cor e Forma:SolidPeso molecular:338.98GLS1 Inhibitor-6
<p>GLS1 Inhibitor-6: IC50=68nM, 220x more selective for GLS2, has anti-tumor and pro-apoptosis effects.</p>Fórmula:C37H52N6O3SCor e Forma:SolidPeso molecular:660.91PARP1/BRD4-IN-2
<p>PARP1/BRD4-IN-2, a potent inhibitor of PARP1 and BRD4, halts cell cycle, triggers apoptosis, and has antitumor effects on TNBC.</p>Fórmula:C25H20N4O4Cor e Forma:SolidPeso molecular:440.45WYJ-2
CAS:<p>WYJ-2, a selective agonist for toll-like receptor 2/1 (TLR2/1), demonstrates an EC50 of 18.57 nM in HEK 293T cells transiently co-transfected with human TLR2 and TLR1. It induces pyroptosis and has shown anticancer activity against non-small cell lung cancer (NSCLC) [1].</p>Fórmula:C17H9F2N3O4Cor e Forma:SolidPeso molecular:357.27JH-XVII-10
<p>JH-XVII-10: potent, oral DYRK1A/B inhibitor (IC50: 3/5 nM), shows antitumor activity in HNSCC.</p>Fórmula:C21H16F4N8OCor e Forma:SolidPeso molecular:472.4CCT369260
CAS:<p>CCT369260 (compound 1), an orally active inhibitor targeting B-cell lymphoma 6 (BCL6), demonstrates anti-tumor efficacy with an IC50 value of 520 nM [1].</p>Fórmula:C24H31ClF2N6O2Cor e Forma:SolidPeso molecular:508.99RET-IN-11
<p>RET-IN-11 selectively inhibits RET (IC50: 6.20 nM), promotes apoptosis, and hinders cell proliferation and migration.</p>Fórmula:C27H30FN9OCor e Forma:SolidPeso molecular:515.59Etalocib sodium
CAS:Etalocib (LY293111) sodium is an orally active leukotriene B4 (LTB4) receptor antagonist with a Ki value of 25 nM for inhibiting [3H]LTB4 binding. It exhibits an IC50 of 20 nM against LTB4-induced calcium mobilization. Additionally, Etalocib sodium can induce apoptosis.Fórmula:C33H32FNaO6Cor e Forma:SolidPeso molecular:566.59ZLHQ-5f
<p>ZLHQ-5f inhibits CDK2/Topo I, with IC50 of 0.145μM for CDK2/CycA2, and promotes apoptosis by arresting HCT116 cells in S phase.</p>Fórmula:C28H25N5O2Cor e Forma:SolidPeso molecular:463.53TNF-α-IN-2
CAS:<p>TNF-α-IN-2 is orally active TNFα inhibitor that distorts the TNFα trimer, causing abnormal signal transduction when it binds to TNFR1, rheumatoid arthritis.</p>Fórmula:C25H21ClF2N6OPureza:99.92%Cor e Forma:SolidPeso molecular:494.92Flizasertib
CAS:<p>Flizasertib is a serine/threonine kinase inhibitor that acts by inhibiting RIPK1, which has anti-inflammatory and therapeutic effects on immune disorders.</p>Fórmula:C15H14FN3OPureza:99.39% - 99.57%Cor e Forma:SolidPeso molecular:271.29tDHU, acid
CAS:<p>tDHU, acid is a dihydropyrimidine cereblon ligand consisting of an E3 ligase ligand and a benzoic acid linker. It serves as an E3 ubiquitin ligase ligand-linker conjugate in the development of PROTACs.</p>Fórmula:C12H12N2O4Peso molecular:248.23Thalidomide-NH-amido-C4-NH2
CAS:<p>Thalidomide-NH-amido-C4-NH2 is a synthetic E3 ligase ligand-linker conjugate composed of a Thalidomide-based cereblon ligand and a linker, which is utilized in the synthesis of PROTAC.</p>Fórmula:C19H23N5O5Peso molecular:401.42RIPK1-IN-23
CAS:<p>RIPK1-IN-23 (compound 19) is an RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 = 1.7 nM). Additionally, RIPK1-IN-23 exhibits anti-inflammatory properties.</p>Fórmula:C27H22N6O3Peso molecular:478.50FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Fórmula:C29H35N7Cor e Forma:SolidPeso molecular:481.64GL0388
<p>GL0388, a Bax activator, induces apoptosis, hinders breast cancer growth, and has IC50 of 0.299-1.57 μM.</p>Fórmula:C21H17FN2OCor e Forma:SolidPeso molecular:332.37Antiproliferative agent-8
<p>Compound 5a, an anticancer agent, enhances P53 and has antiproliferative effects.</p>Fórmula:C22H16ClN3O3Cor e Forma:SolidPeso molecular:405.83Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride
CAS:<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, comprised of a cereblon ligand based on Thalidomide and a linker, utilized in the synthesis of PROTACs.</p>Fórmula:C21H28ClN5O7Peso molecular:497.93KIRA9
<p>KIRA9 inhibits IRE1 with a 4.8 μM IC50, blocking ER-stress-induced mRNA decay and apoptosis by fully binding IRE1's ATP site.</p>Fórmula:C27H27F3N6O3SCor e Forma:SolidPeso molecular:572.6MDK-3345
CAS:<p>MDK-3345 is a reversible covalent inhibitor for Mcl-1.</p>Fórmula:C36H34BN3O7Pureza:98%Cor e Forma:SolidPeso molecular:631.48BMS-751324
CAS:<p>BMS-751324: p38α MAPK inhibitor with carbamyl-methyl, esters, phosphate from HPA. Reduces rat arthritis swelling and TNFα.</p>Fórmula:C32H35N6O10PCor e Forma:SolidPeso molecular:694.63Antiangiogenic agent 7
CAS:<p>Antiangiogenic agent 7 (Compound 1) induces apoptosis, elevates Reactive Oxygen Species (Reactive Oxygen Species), and inhibits the intracellular enzyme thioredoxin reductase. It exhibits anticancer activity with IC50 values ranging from 0.08 to 3.5 μM against cervical cancer cells (HeLa), prostate cancer cells (PC-3), and non-small cell lung cancer cells (A549). Additionally, Antiangiogenic agent 7 suppresses tumor growth in a mouse xenograft model.</p>Fórmula:C24H26AuN3P2SCor e Forma:SolidPeso molecular:647.46CRI9
<p>CRI9 effectively inhibits the c-MET/PI3K/Akt/mTOR axis, suppressing the proliferation of hepatocellular carcinoma (HCC) cells. This compound exhibits potent cytotoxicity against HCC cells and induces apoptosis.</p>Fórmula:C26H18N6O4Cor e Forma:SolidPeso molecular:478.463′-Hydroxyflavanone
CAS:<p>3′-Hydroxyflavanone is a cyclized flavonoid with anti-tumor properties that induces apoptosis in HeLa cells.</p>Fórmula:C15H12O3Cor e Forma:SolidPeso molecular:240.25EGFR-IN-134
<p>EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.</p>Fórmula:C36H30N6O5Cor e Forma:SolidPeso molecular:626.66BRD-K56819078
CAS:<p>BRD-K56819078, a Bcl-2 inhibitor, significantly reduces the burden of senescent cells and the mRNA expression of aging-related genes in the kidneys. It exerts its anti-aging effects by inhibiting cell apoptosis (apoptosis).</p>Fórmula:C24H20FN3O4S2Cor e Forma:SolidPeso molecular:497.56PF-07328948
CAS:<p>PF-07328948 is a branched-chain keto-acid dehydrogenase kinase (BDK) inhibitor, useful for studying CVD metabolic disorders.</p>Fórmula:C16H8F4O3SPureza:98.42%Cor e Forma:SolidPeso molecular:356.29Lometrexol
CAS:<p>Lometrexol (LY 264618) is an antifolate that inhibits GARFT, blocks purine synthesis, induces apoptosis, and has anticancer properties.</p>Fórmula:C21H25N5O6Pureza:97.76% - 99.56%Cor e Forma:SolidPeso molecular:443.45Milademetan
CAS:<p>Milademetan (DS-3032), an MDM2 inhibitor, exhibits antitumor activity, induces G1 cell cycle arrest and apoptosis, and can be used to study solid tumors.</p>Fórmula:C30H34Cl2FN5O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:618.53Tuvusertib
CAS:<p>Tuvusertib (M1774), an oral ATR inhibitor (Ki<1µM), selectively blocks CHK1 phosphorylation, disrupts DNA repair, and induces tumor cell apoptosis.</p>Fórmula:C16H12F2N8OPureza:98.44% - 99.66%Cor e Forma:SolidPeso molecular:370.32SY-5609
CAS:<p>SY-5609 (CDK7-IN-3) is a selective non-covalent CDK7 inhibitor, with weak inhibitory activity against CDK2, CDK9 and CDK12.Cost-effective and quality-assured.</p>Fórmula:C23H26F3N6OPPureza:99.34% - >99.99%Cor e Forma:SolidPeso molecular:490.46Vatalanib hydrochloride
CAS:<p>Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.</p>Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27Zotatifin
CAS:<p>Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and antitumor properties, inhibiting Sox4 translation and inducing apoptosis.</p>Fórmula:C28H29N3O5Pureza:98.85%Cor e Forma:SolidPeso molecular:487.55HC-5404
CAS:<p>HC-5404 is a potent and selective PERK inhibitor, blocking the activation of the PERK pathway, anti-tumor effects, advanced solid tumors and renal cell Cancer.</p>Fórmula:C24H24F2N4O3Pureza:99.33%Cor e Forma:SolidPeso molecular:454.47BCL6-IN-3
CAS:<p>BCL6-IN-3: potent BCL6 inhibitor, 70 nM GI50 in SU-DHL4, affects cell functions, antitumor.</p>Fórmula:C24H31ClF2N6O2Pureza:98.17%Cor e Forma:SolidPeso molecular:508.99UH15-38
CAS:<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>Fórmula:C26H27N5O2Pureza:99.85%Cor e Forma:SolidPeso molecular:441.53Gemcitabine elaidate hydrochloride
CAS:<p>CP-4126, a lipophilic pro-drug of Gemcitabine, converts to active form by esterases, allowing oral administration with dose-dependent effects.</p>Fórmula:C27H44ClF2N3O5Pureza:98.50% - 99.6%Cor e Forma:SolidPeso molecular:564.11JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59FX-11
CAS:<p>FX-11: potent LDHA inhibitor (Ki 8 μM), activates PKM2, reduces ATP, induces oxidative stress/ROS, cell death, shows antitumor effects.</p>Fórmula:C22H22O4Pureza:98.95%Cor e Forma:SolidPeso molecular:350.41PIM-447 dihydrochloride
CAS:<p>PIM-447 dihydrochloride is an orally available and selective inhibitor of pan-PIM kinase(Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38WEHI-539 hydrochloride
CAS:<p>WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.</p>Fórmula:C31H30ClN5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:620.18OBAA
CAS:<p>OBAA is a potent inhibitor of phospholipase A2 (PLA2) with an IC 50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC 50 of 0.4 μM [1] [2] [3].</p>Fórmula:C28H44O3Pureza:98%Cor e Forma:SolidPeso molecular:428.65(R)-Verapamil hydrochloride
CAS:<p>(R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is an inhibitor of P-Glycoprotein.</p>Fórmula:C27H39ClN2O4Cor e Forma:SolidPeso molecular:491.06β-Zearalanol
CAS:Beta-Zearalenol, a derivative of zearalenone (ZEA) capable of conjugating with glucuronic acid[2], is a mycotoxin produced by Fusarium spp. It induces apoptosis and oxidative stress in mammalian reproductive cells[1].Fórmula:C18H26O5Cor e Forma:SolidPeso molecular:322.4AP1867-3-(aminoethoxy)
CAS:<p>AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p>Fórmula:C38H50N2O9Cor e Forma:SolidPeso molecular:678.81Actinonin
CAS:<p>Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces and a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. It also induces apoptosis and inhibits aminopeptidase M, aminopeptidase N, and leucine aminopeptidase, as well as MMP-1, MMP-3, MMP-8, MMP-9, and meprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin exhibits antiproliferative and antitumor activities [1][2][3][4][5].</p>Fórmula:C19H35N3O5Cor e Forma:SolidPeso molecular:385.5Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-
CAS:Fórmula:C6H10N2O4PtPureza:98%Cor e Forma:SolidPeso molecular:369.2326Ref: IN-DA00I84B
Produto descontinuado5-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide
CAS:Fórmula:C9H14N4O5Pureza:95%Cor e Forma:SolidPeso molecular:258.2313Mcl-1 inhibitor 6
CAS:<p>Mcl-1 inhibitor 6 binds Mcl-1 with KD 0.23 nM and Ki 0.02 μM, shows strong selectivity over Bcl-2 family, and demonstrates antitumor efficacy.</p>Fórmula:C26H28ClNO6SCor e Forma:SolidPeso molecular:518.02MI-773
CAS:<p>MI-773 is a potent inhibitor of the MDM2-p53 protein interaction (PPI) with a high affinity for MDM2 and a Kd value of 8.2 nM. MI-773 exhibits antitumour effects.</p>Fórmula:C29H34Cl2FN3O3Cor e Forma:SolidPeso molecular:562.5Ingenol 3,20-dibenzoate
CAS:<p>Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms that effectively induces the translocation of nPKC-delta, -epsilon, and -theta, as well as PKC-mu, from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].</p>Fórmula:C34H36O7Cor e Forma:SolidPeso molecular:556.65Prostaglandin A2
CAS:<p>PGA2 is a naturally occurring prostaglandin in gorgonian corals where it may function in self defense. It is generally not present in mammals. PGA2 has low biological potency in most bioassays, but it does show some antiviral/antitumor activity.[1] At a 25 uM concentration, PGA2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase .[2] It has also been shown to act as a vasodilator with natriuretic properties.[3]</p>Fórmula:C20H30O4Cor e Forma:SolidPeso molecular:334.45ENMD-2076 tartrate
CAS:<p>ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.</p>Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56Ciprofloxacin lactate
CAS:<p>Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.</p>Fórmula:C20H24FN3O6Cor e Forma:SolidPeso molecular:421.43Ac-IETD-CHO TFA
<p>Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.</p>Fórmula:C23H35F3N4O12Cor e Forma:SoildPeso molecular:616.54Vatiquinone
CAS:<p>Vatiquinone, also known as EPI 743, is an orally bioavailable para-benzoquinone being developed for inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhanc</p>Fórmula:C29H44O3Cor e Forma:SolidPeso molecular:440.66Thalidomide-O-C6-COOH
CAS:<p>Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).</p>Fórmula:C20H22N2O7Cor e Forma:SolidPeso molecular:402.403RRD-251
CAS:<p>RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].</p>Fórmula:C8H9Cl3N2SCor e Forma:SolidPeso molecular:271.59Yatein
CAS:<p>Yatein inhibits herpes simplex virus type 1 replication by interruption the immediate-early gene expression. Yatein is a lignan isolated from A. chilensis. It also has antiproliferative activity.</p>Fórmula:C22H24O7Pureza:98%Cor e Forma:SolidPeso molecular:400.42XMU-MP-3
CAS:<p>XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.</p>Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563Swainsonine
CAS:<p>Swainsonine (Tridolgosir) is an alkaloid isolated from Astragalus membranaceus and is a potent and reversible inhibitor of alpha-mannosidase. swainsonine has antitumour activity and induces apoptosis and cell cycle arrest in the G2/M phase.</p>Fórmula:C8H15NO3Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:173.21Thalidomide-5-COOH
CAS:<p>Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.</p>Fórmula:C14H10N2O6Cor e Forma:SolidPeso molecular:302.242A-192621
CAS:<p>A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).</p>Fórmula:C33H38N2O6Pureza:98%Cor e Forma:SolidPeso molecular:558.66SCH79797
CAS:<p>SCH79797 is a potent and specific protease-activated receptor 1 (PAR1) antagonistwith antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects.</p>Fórmula:C23H25N5Pureza:99.80%Cor e Forma:SolidPeso molecular:371.48Carubicin hydrochloride
CAS:<p>Carubicin HCl is an anthracycline antineoplastic antibiotic. Through intercalates into DNA and interacts with topoisomerase II, Carubicin inhibits DNA replication and repair and RNA and protein synthesis.</p>Fórmula:C26H28ClNO10Cor e Forma:SolidPeso molecular:549.95DB818
CAS:<p>DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.</p>Fórmula:C19H16N6SPureza:98%Cor e Forma:SolidPeso molecular:360.44Thalidomide-O-amido-C4-NH2 hydrochloride
CAS:<p>Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].</p>Fórmula:C19H23ClN4O6Pureza:98%Cor e Forma:SolidPeso molecular:438.86Imifoplatin
CAS:<p>Imifoplatin (PT-112) is a platinum compound with antitumor activity and may be used to study prostate cancer and immune system disorders.</p>Fórmula:C6H16N2O7P2PtPureza:≥95.0%Cor e Forma:SolidPeso molecular:485.23Thalidomide-O-C5-NH2 hydrochloride
CAS:<p>Thalidomide-O-C5-NH2 hydrochloride is a synthetic compound consisting of a ligand-linker conjugate with E3 ligase activity. It combines a cereblon ligand based on Thalidomide and a linker commonly utilized in PROTAC technology.</p>Fórmula:C18H22ClN3O5Cor e Forma:SolidPeso molecular:395.84CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73anti-TNBC agent-2
CAS:<p>Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic.</p>Fórmula:C28H37ClFN7OPureza:98%Cor e Forma:SolidPeso molecular:542.09Ref: TM-T79699
Produto descontinuadoTaltobulin
CAS:<p>Taltobulin (HTI-286) is a synthetic analog of the tripeptide cysteine, a microtubule protein inhibitor that inhibits liver tumor cell proliferation in vitro and tumor growth in vivo.Taltobulin is cytotoxic, induces mitotic arrest and apoptosis, and may be used in the study of breast cancer and microtubule tissue-related diseases.</p>Fórmula:C27H43N3O4Pureza:99.86%Cor e Forma:SolidPeso molecular:473.65IHMT-MST1-39
CAS:<p>IHMT-MST1-39 is an orally effective MST kinase inhibitor with IC50 values of 42 nM for MST1 and 109 nM for MST2. It activates the AMPK signaling pathway in hepatocytes and inhibits apoptosis in pancreatic β cells. Additionally, IHMT-MST1-39 improves type 1 diabetes in mice induced by Streptozotocin.</p>Fórmula:C20H18F2N6O3SCor e Forma:SolidPeso molecular:460.46Ref: TM-T200512
Produto descontinuadoSMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1 that demonstrates the capability to reduce cell viability and colony formation. Additionally, SMIP34 induces cell apoptosis (apoptosis) and causes cell cycle arrest in the S phase. It reduces the expression of PELP1 and exhibits anti-tumor activity. SMIP34 also has potential for research in triple-negative breast cancer (TNBC).</p>Fórmula:C20H15ClFN5O2SCor e Forma:LiquidPeso molecular:443.88CHMFL-48
CAS:<p>CHMFL-48, an orally active inhibitor of BCR-ABL kinase, demonstrates efficacy against both the wild-type (wt) and various imatinib-resistant mutants. It exhibits potent inhibitory activity, with IC 50 values of 1 nM for the ABL wild-type and 0.8 nM for the ABL T315I mutant. CHMFL-48 operates by inhibiting the autophosphorylation of both wild-type and mutant BCR-ABL, affecting downstream signaling mediators including STAT5 and CRKL. This disruption leads to cell cycle arrest and triggers apoptosis. Given its properties, CHMFL-48 is a promising candidate for research on chronic myeloid leukemia (CML).</p>Fórmula:C31H30F3N7OCor e Forma:SolidPeso molecular:573.61DETD-35
CAS:<p>DETD-35 is a promising chemical compound in anti-melanoma therapy, functioning as an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways. It enhances cancer cell apoptosis (Apoptosis) and diminishes resistance to Vemurafenib in cancer cells. The compound exhibits IC 50 values of 2.7, 6.0, 3.9, 3.1, and 2.5 μM against melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c, respectively. DETD-35 offers significant potential for advancing research in melanoma treatment strategies.</p>Fórmula:C27H24O6Cor e Forma:SolidPeso molecular:444.48ZSQ836
CAS:<p>ZSQ836 is a dual covalent inhibitor of CDK12/CDK13 with oral bioactivity, displaying an EC50 value of 32 nM against CDK12. This compound can induce cell apoptosis (apoptosis) and demonstrates in vivo anticancer properties. ZSQ836 is applicable for research in ovarian cancer.</p>Fórmula:C27H28AsClN6OS2Cor e Forma:SolidPeso molecular:627.05Ref: TM-T200333
Produto descontinuadoCyy-272
CAS:<p>Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25, 1.07, and 1.24 μM against JNK1, JNK2, and JNK3, respectively. It exerts anti-inflammatory effects by inhibiting the phosphorylation of JNK, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS). Moreover, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissues caused by high lipid concentrations, further mitigating resultant cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 is utilized in the study of obesity-related myocarditis.</p>Fórmula:C23H23F2N7Cor e Forma:SolidPeso molecular:435.47Ref: TM-T200453
Produto descontinuado



